This company has shut down. HilleVax is no longer operating — its last tracked round was a Post-IPO Equity in 2023.
Explore the Startup GraveyardHilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
HilleVax has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2023.
HilleVax's investors include Lightspeed Venture Partners, RA Capital Management, Samsara BioCapital, Perceptive Advisors, Abingworth.
HilleVax is headquartered in Boston, United States.
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
HilleVax is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HilleVax — Funding & Investors." VCBacked, September 19, 2023, https://www.vcbacked.co/company/hillevax. Accessed August 14, 2026.
VCBacked. (2023). HilleVax — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/hillevax
{{cite web |title=HilleVax — Funding & Investors |url=https://www.vcbacked.co/company/hillevax |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated